Kay N E, Oken M M, Mazza J J, Bradley E C
Department of Medicine, Veterans Administration Medical Center, Minneapolis, MN.
Nouv Rev Fr Hematol (1978). 1988;30(5-6):475-8.
Recombinant interleukin-2 (rIL-2) is a biologic response modifier that is capable of enhancing or restoring the cytolytic capacity of large granular lymphocytes (LGL). We utilized this biologic response modifier in the treatment of B-chronic lymphocytic leukemia (B-CLL), a disease frequently characterized by deficient or absent natural killer activity. B-CLL (n = 12) patients previously refractory to chemotherapy or with progressive disease post cessation of chemotherapy were eligible. rIL-2 was given as i.v. infusion (2 x 10(6) units/m2) over 2 h 5 times per week for 3 weeks as induction. Responding patients were placed on maintenance therapy. Although there were no complete or partial responses (by ECOG criteria) there was clear evidence of tumor reduction. Seven of 10 evaluable patients had a reduction of the peripheral blood B cell clone, 3 had node reduction and 2 had reduction in their splenomegaly. All patients experienced mild to moderate toxicity and 1 patient died while on induction therapy. Three B-CLL patients following induction rIL-2 treatment were placed back on chemotherapy because of progressive disease. Interestingly, these 2 B-CLL patients achieved extremely rapid and complete responses to chemotherapy which had previously been ineffective. These data suggest a possible role for rIL-2 in treatment of B-CLL.
重组白细胞介素-2（rIL-2）是一种生物反应调节剂，能够增强或恢复大颗粒淋巴细胞（LGL）的细胞溶解能力。我们将这种生物反应调节剂用于治疗B细胞慢性淋巴细胞白血病（B-CLL），该病常表现为自然杀伤活性不足或缺乏。符合条件的是12例先前对化疗耐药或化疗停止后病情进展的B-CLL患者。诱导治疗时，rIL-2通过静脉输注给药（2×10⁶单位/m²），每周5次，每次2小时，共3周。有反应的患者接受维持治疗。虽然没有完全缓解或部分缓解（根据东部肿瘤协作组标准），但有明确的肿瘤缩小证据。10例可评估患者中有7例外周血B细胞克隆减少，3例淋巴结缩小，2例脾肿大减轻。所有患者均经历了轻度至中度毒性反应，1例患者在诱导治疗期间死亡。3例诱导rIL-2治疗后的B-CLL患者因病情进展重新接受化疗。有趣的是，这2例B-CLL患者对先前无效的化疗实现了极其迅速和完全的反应。这些数据表明rIL-2在B-CLL治疗中可能发挥作用。
